AZAFAROS - A Beacon for People Living with Severe Rare Metabolic Disorders AZAFAROS ENTERS CLINICAL STAGE WITH AZ-3102, AN ORAL SMALL MOLECULE BEING DEVELOPED FOR RARE NEUROGENETIC DISORDERS >>>